Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
The company is headquartered in Langhorne, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 5, 25 | -0.13 Decreased by -44.44% | -0.11 Decreased by -14.04% |
| Nov 7, 24 | -0.11 Decreased by -14.50% | -0.11 Decreased by -4.09% |
| Aug 12, 24 | -0.12 Decreased by -71.43% | -0.11 Decreased by -9.09% |
| May 9, 24 | -0.11 Decreased by -57.14% | -0.10 Decreased by -10.00% |
| Mar 7, 24 | -0.09 Decreased by -28.57% | -0.10 Increased by +10.00% |
| Nov 9, 23 | -0.10 Decreased by -42.86% | -0.07 Decreased by -42.86% |
| Aug 10, 23 | -0.07 Decreased by -16.67% | -0.08 Increased by +12.50% |
| May 15, 23 | -0.07 Decreased by -40.00% | -0.07 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 272.00 K Increased by +N/A% | -29.04 M Decreased by -80.41% | Decreased by -10.68 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -24.25 M Decreased by -46.08% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -22.24 M Decreased by -94.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -20.35 M Decreased by -147.01% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -16.10 M Decreased by -45.09% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -16.60 M Decreased by -62.15% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -11.44 M Decreased by -18.89% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -8.24 M Increased by +3.71% | Decreased by N/A% Decreased by N/A% |